The American Cancer Society has issued a new clinical practice guideline for the follow-up screening and care coordination for this population of survivors, who may experience significant physical, psychosocial, and practical effects from their cancer and its treatment.
A study published by researchers at the Dana Farber-Cancer Institute recently discovered that financial status plays a large role in the level of symptom burden and quality of life for patients newly diagnosed with lung or colorectal cancer.
Findings from a randomized trial reported at the 2016 Annual Meeting of the Society of Gynecologic Oncology showed that APF530, an extended-release formulation of the antiemetic granisetron, achieved a complete response more often than did ondansetron in patients receiving highly emetogenic cisplatin-based chemotherapy.
Pregnant and diagnosed with cervical cancer at age 27, I chose treatment and my daughter and I survived what experts said would kill us.
Again this year, the American Society of Clinical Oncology has released its report on the state of cancer care in the United States.
A majority of patients with cancer who undergo chemotherapy experience neuropathy as result of the treatment, and a new study conducted by researchers at The University of Texas MD Anderson Cancer Center suggests that neurofeedback can reduce the pain associated with the condition and improve quality of life.
A new study by physicians has found that Twitter may be an effective and heretofore untapped resource to stimulate interest in cancer clinical trials and boost enrollment.
Is there a treatment-related survival benefit for older patients with metastatic colorectal cancer?
Crizotinib (Xalkori) has been approved by the FDA as a treatment for patients with ROS1-positive metastatic non–small cell lung cancer.
Drawing a standing ovation from a packed room of oncology professionals attending the 33rd Annual Miami Breast Cancer Conference®, breast cancer survivor and Good Morning America news anchor Amy Robach criticized new US Preventive Services Task Force guidelines that extend the recommended age to begin mammogram screening to age 50 for women at average risk.
Bright Pink's Women's Health Provider Education program is designed to address gaps in knowledge of young women's genetic cancer risk.
The results of this study underscore the importance of advance care planning in improving the quality of care that patients receive at end-of-life.
Encouraging findings for PD-1 inhibitor–based immunotherapies for the treatment of patients with metastatic head and neck cancer are emerging from clinical studies.
The American Society of Clinical Oncology convened a panel of experts to provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer.
An impressive improvement in progression-free survival (PFS) in the RESONATE-2 trial led to the FDA’s approval of ibrutinib (Imbruvica) March 4 for the frontline treatment of chronic lymphocytic leukemia, based on data from the RESONATE-2 trial.
A new white paper released by CancerCare provides evidence and guidance for integrating quality of life measures for patients with lung cancer in routine clinical care.
The first study to assess smoking habits of women with breast cancer before and after diagnosis has found that those who quit smoking after their diagnosis had a 33% lower risk of dying of the disease than those who continued to smoke.
Study finds that genetic counseling before genetic testing provides greater knowledge and satisfaction with the process.
The benefits of 3D mammography are durable, increasing detection of breast cancers and reducing anxiety over callbacks, according to a recent study that provides the first longitudinal evidence of the utility of this approach.
Within 6 years of HPV vaccine introduction, there was a 64% decrease in 4vHPV type prevalence among females aged 14-19 years and a 34% decrease among those aged 20-24 years.
Racial disparities in mortality for breast cancer have gotten worse in women and persisted for colorectal cancer in men, although progress has been made in closing the mortality gap between blacks and whites for other cancers.
The FDA approved the mTOR inhibitor everolimus (Afinitor) for the treatment of adult patients with progressive, well-differentiated non-functional, locally advanced or metastatic gastrointestinal or lung neuroendocrine tumors.
Melanoma survivor and Cancer Hope Network Support Volunteer Sam Lozier on why it's important for patients to become CEO's of their own health and remember that treatment is a partnership.
Empowering patients with prostate cancer and their caregivers through practical information and insight into the medical world to help them be better informed.
The Julie Fund for Women’s Cancers remains single largest philanthropic source of funding for ovarian cancer research at Massachusetts General Hospital.
Patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen, will have a new treatment option, following the FDA’s approval of obinutuzumab (Gazyva).
Patients with pretreated, HR-positive, HER2-negative metastatic breast cancer can now receive palbociclib (Ibrance) for use in combination with fulvestrant following the FDA’s recent approval of this new indication for the CDK 4/6 inhibitor.
The American Society of Clinical Oncology released its annual report, now in its 11th year, which documents the progress being made in clinical cancer research and identifies future research directions.
A study involving nearly 30,000 patients diagnosed with early-stage breast cancer has found that up to 60% of these women received imaging tests such as CT, bone, and PET scans that were not medically justified, contrary to national guidelines.
